The bladder is an important organ in the human body. It serves as a reservoir for urine, allowing us to control when and where we urinate. It also helps to regulate the pressure of our urine and keep it from becoming too concentrated. As such, any issues with the bladder can be extremely uncomfortable and even dangerous. One such issue is the presence of bladder stones, which can cause pain and difficulty in urinating. Fortunately, there is a new approach to treating bladder stones known as fulgurating. In this article, we will explore what fulgurating is and how it can be used to treat bladder stones.
Fulgurating is a minimally invasive procedure used to treat bladder stones. The procedure involves using a special device to generate an electric current which is then directed at the bladder stone. This current causes the stone to break up into smaller pieces, which are then flushed out of the bladder. The procedure is performed under general anaesthesia, and usually takes less than an hour.
Fulgurating offers several advantages over traditional bladder stone treatments. Firstly, it is a minimally invasive procedure, meaning that it requires no major surgery and is less likely to cause complications. Secondly, it is a relatively quick procedure, with most treatments taking less than an hour. Thirdly, fulgurating is a relatively safe procedure with a low risk of complications. Finally, it is a relatively affordable procedure, with most treatments costing less than traditional treatments.
Although fulgurating is a relatively safe procedure, there are some potential risks associated with it. These include the risk of infection, bleeding, damage to the bladder wall, and complications from the anaesthetic. In addition, there is a risk of the stone re-forming after the procedure. For this reason, it is important to ensure that the stone has been completely broken up before flushing it out.
Fulgurating can be used to treat bladder stones in both adults and children. However, it is important to note that the procedure is not suitable for everyone. It is generally only recommended for those with small bladder stones, as larger stones may require more invasive treatments. In addition, it is not suitable for those with certain medical conditions, such as kidney disease or a weakened immune system.
Fulgurating is a minimally invasive procedure used to treat bladder stones. It offers several advantages over traditional treatments, including being quick, safe, and relatively affordable. However, it is not suitable for everyone and there are some potential risks associated with the procedure. For this reason, it is important to consult with a doctor before undergoing fulgurating to ensure that it is the right treatment for you. Overall, fulgurating is an effective and safe way to treat bladder stones, and can provide much-needed relief from the discomfort and pain associated with them.
1.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
2.
Team finds broken 'brake' on cancer mutation machine.
3.
Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer
4.
Prostate cancer screening program beneficial in top decile of polygenic risk score
5.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
1.
New Research on Craniopharyngioma
2.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
3.
A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments
4.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
5.
The Mysterious World of Petechiae: Exploring Causes and Treatments
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Navigating the Complexities of Ph Negative ALL - Part XV
5.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation